UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
------------------
For the month of May 2004
Commission File Number: 001-31368
SANOFI-SYNTHELABO
(Translation of registrant's name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
-----
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):
-----
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes [ ] No [X]
If "Yes" marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-________
This Report on Form 6-K shall be deemed to be incorporated by reference
into Sanofi-Synthelabo's Registration Statement on Form F-4 (Registration No.
333-112314), as post-effectively amended and declared effective on May 13, 2004
by the United States Securities Exchange Commission, and the related prospectus
filed on April 12, 2004 pursuant to Rule 424(b) under the United States
Securities Act of 1933, as amended, and shall be part thereof from the date on
which this Report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.
[Sanofi-Synthelabo Logo]
Investor Relations Paris, May 14th, 2004
SANOFI-SYNTHELABO'S SHAREHOLDERS MEETING
AND OFFER FOR AVENTIS
On May 13, 2004, the Board of Directors of Sanofi-Synthelabo set June 23, 2004
as the date for Sanofi-Synthelabo's joint general and extraordinary meeting of
shareholders and finalized the meeting's agenda, the extraordinary portion of
which consists of the increase in share capital intended to pay for the Aventis
shares tendered in Sanofi-Synthelabo's offer for Aventis.
On May 12, 2004, Aventis announced that the Management Board of Aventis has set
June 11 as the date of the annual general meeting of Aventis (in the likely
event that it is held on its second convocation). In particular, this meeting is
expected to approve the 2003 dividend in the amount of (euro)0.82 per share,
with an ex-dividend date of June 15, 2004 and a payment date of July 15, 2004.
As a result, in accordance with the terms of Sanofi-Synthelabo's revised offer
for Aventis and subject to the condition that this dividend is approved by the
annual general meeting of Aventis, the terms of the Sanofi-Synthelabo's offer
for Aventis would be adjusted in the following manner :
o Standard entitlement : 5 Sanofi-Synthelabo ordinary shares and (euro)115.08 in
cash for 6 Aventis ordinary shares (or 0.8333 of a
Sanofi-Synthelabo ordinary share and (euro)19.18 in
cash for each Aventis ordinary share; and 1.6667
Sanofi-Synthelabo ADSs and an amount in U.S. dollars
equal to (euro)19.18 in cash for each Aventis ADS)
o All stock election : 1.1600 Sanofi-Synthelabo ordinary shares for each
Aventis ordinary share (or 2.3200 Sanofi-Synthelabo
ADSs for each Aventis ADS)
1/3
o All cash election : (euro)68.11 in cash for each Aventis ordinary share
(or an amount in U.S. dollars equal to(euro)68.11 in
cash for each Aventis ADS).
This adjustment mechanism is more fully described in Section 1.3.2(a) "Terms of
the New Offer for Aventis Shares" in the French prospectus supplement that
obtained the AMF's VISA (no. 04-384) on May 7, 2004 and under the section
entitled "The Revised U.S. Offer -- Consideration Offered after Approval of
Aventis Dividends" in the U.S. prospectus supplement that Sanofi-Synthelabo
intends to distribute shortly.
The offer is expected to close at the end of June 2004.
In accordance with article 7 of the COB rule no. 2002-04, this press release was
transmitted to the Autorite des marches financiers (AMF) before its publication.
This press release contains projections and other statements that are not
historical facts, which are subject to various risks and uncertainties (many of
which are difficult to predict and generally beyond the control of
Sanofi-Synthelabo) that could cause actual results and developments to differ
materially from those expressed, or implied or projected. These risks and
uncertainties include those discussed in our filings with the United States
Securities and Exchange Commission (SEC) and the AMF. Other than as requested by
applicable law, Sanofi-Synthelabo does not undertake any obligation to update
any statement that is not a historical fact.
IMPORTANT INFORMATION: In connection with the proposed acquisition of Aventis,
Sanofi-Synthelabo has filed a registration statement on Form F-4 (File no.
333-112314) , including a prospectus/offer to exchange, and will file additional
documents with the SEC. INVESTORS ARE URGED TO READ THE REGISTRATION STATEMENT,
INCLUDING THE PROSPECTUS/OFFER TO EXCHANGE, AND ANY OTHER RELEVANT DOCUMENTS
FILED WITH THE SEC, INCLUDING ALL AMENDMENTS AND SUPPLEMENTS (INCLUDING ANY
SUPPLEMENT RELATING TO ITS REVISED OFFERS), BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. Free copies of the registration statement, as well as other
relevant documents filed with the SEC, may be obtained at the SEC's web site at
www.sec.gov. The prospectus/offer to exchange and other transaction-related
documents are being mailed to Aventis securityholders eligible to participate in
the U.S. offer and additional copies may be obtained for free from MacKenzie
Partners, Inc., the information agent for the U.S. offer, at the following
address: 105, Madison Avenue, New York, New York 10016; telephone: 1-(212)
929-5500 (call collect) or 1-(800) 322-2885 (toll-free call); e-mail
proxy@mackenziepartners.com. In connection with its revised offer,
Sanofi-Synthelabo intends to distribute a supplement to the prospectus/offer to
exchange as soon as practicable.
In France, holders of Aventis securities are requested, with respect to the
offer, to refer to the prospectus supplement (note d'information
complementaire), which has been granted visa number 04-384 by the Autorite des
marches financiers ("AMF") and which is available on the website of the AMF
(www.amf-france.org) and without cost from: BNP Paribas Securities Services,
GIS-Emetteurs, Service Logistique, Les Collines de l'Arche, 75450 Paris Cedex 9
and to the recommendation statement (note d'information en reponse) of Aventis
when it is available.
The public offer to holders of Aventis ordinary shares located in Germany (the
"German Offer") is being made in accordance with applicable German law and
pursuant to an offer document/sales prospectus, which is available free of
charge at BNP Paribas Securities Services, Gruneburgweg 14, D-60322 Frankfurt am
Main (Fax: 069 - 152 05 277) and on the website of the Company
(www.sanofi-synthelabo.com). Any decision to tender Aventis ordinary shares in
exchange for Sanofi-Synthelabo ordinary shares under the German Offer must be
taken exclusively with regard to the terms and conditions of the German Offer,
as well as with regard to the information included in the offer document/sales
prospectus, including any amendments thereto, issued in Germany.
The French Offer, the U.S. Offer and the German Offer are being made on
substantially the same terms and completion of these offers is subject to the
same conditions. It is intended that the three offers will expire at the same
time.
Investors and security holders may obtain a free copy of the Form 20-F filed
with the SEC on April 2, 2004 and any other documents filed by Sanofi-Synthelabo
with the SEC at www.sec.gov as well as of the Reference Document filed with the
AMF on April 2, 2004 (No. 04-0391) at www.amf-france.org or directly from
Sanofi-Synthelabo on our web site at: www.sanofi-synthelabo.com.
2/3
Investor Relations Department
Phillipe Goupit Director of Investor Relations
Arnaud Delepine Investor Relations Europe
Sanjay Gupta Investor Relations US
Anne d'Halluin-Sulzer Investor Relations
Contacts:
E-mail: investor-relations@sanofi-synthelabo.com
Europe US
Tel: + 33 1 53 77 45 45 Tel: +1 212 551 42 93
Fax: + 33 1 53 77 42 96 Fax: +1 212 551 49 92
3/3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Dated: May 14, 2004 SANOFI-SYNTHELABO
By: /s/ MARIE-HELENE LAIMAY
--------------------------------
Name: Marie-Helene Laimay
Title: Senior Vice President and
Chief Financial Officer